vs
Side-by-side financial comparison of Mayville Engineering Company, Inc. (MEC) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Mayville Engineering Company, Inc. is the larger business by last-quarter revenue ($134.3M vs $103.7M, roughly 1.3× Twist Bioscience Corp). Mayville Engineering Company, Inc. runs the higher net margin — -3.2% vs -29.4%, a 26.2% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 10.7%). Mayville Engineering Company, Inc. produced more free cash flow last quarter ($10.2M vs $-34.8M).
Mayville Engineering Company, Inc. is a U.S.-headquartered leading manufacturer of metal components, fabricated assemblies, and custom engineered solutions. It serves OEM clients across agriculture, construction, transportation, defense, and power sports markets, offering end-to-end services from prototyping to high-volume production for North America.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
MEC vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $134.3M | $103.7M |
| Net Profit | $-4.4M | $-30.5M |
| Gross Margin | 6.8% | 52.0% |
| Operating Margin | -4.1% | -31.7% |
| Net Margin | -3.2% | -29.4% |
| Revenue YoY | 10.7% | 16.9% |
| Net Profit YoY | -127.3% | 3.4% |
| EPS (diluted) | $-0.22 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $134.3M | $103.7M | ||
| Q3 25 | $144.3M | — | ||
| Q2 25 | $132.3M | — | ||
| Q1 25 | $135.6M | — | ||
| Q4 24 | $121.3M | — | ||
| Q3 24 | $135.4M | — | ||
| Q2 24 | $163.6M | — | ||
| Q1 24 | $161.3M | — |
| Q4 25 | $-4.4M | $-30.5M | ||
| Q3 25 | $-2.7M | — | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $20.0K | — | ||
| Q4 24 | $16.0M | — | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $3.8M | — | ||
| Q1 24 | $3.2M | — |
| Q4 25 | 6.8% | 52.0% | ||
| Q3 25 | 11.0% | — | ||
| Q2 25 | 10.3% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 13.6% | — | ||
| Q1 24 | 13.0% | — |
| Q4 25 | -4.1% | -31.7% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 19.0% | — | ||
| Q3 24 | 4.2% | — | ||
| Q2 24 | 5.0% | — | ||
| Q1 24 | 4.7% | — |
| Q4 25 | -3.2% | -29.4% | ||
| Q3 25 | -1.9% | — | ||
| Q2 25 | -0.8% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | $-0.22 | $-0.50 | ||
| Q3 25 | $-0.13 | — | ||
| Q2 25 | $-0.05 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $0.76 | — | ||
| Q3 24 | $0.14 | — | ||
| Q2 24 | $0.18 | — | ||
| Q1 24 | $0.16 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $240.7M | $456.1M |
| Total Assets | $563.6M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5M | $197.9M | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $206.0K | — | ||
| Q1 25 | $183.0K | — | ||
| Q4 24 | $206.0K | — | ||
| Q3 24 | $178.0K | — | ||
| Q2 24 | $314.0K | — | ||
| Q1 24 | $314.0K | — |
| Q4 25 | $240.7M | $456.1M | ||
| Q3 25 | $244.8M | — | ||
| Q2 25 | $246.8M | — | ||
| Q1 25 | $250.0M | — | ||
| Q4 24 | $251.8M | — | ||
| Q3 24 | $238.4M | — | ||
| Q2 24 | $238.1M | — | ||
| Q1 24 | $234.0M | — |
| Q4 25 | $563.6M | $638.1M | ||
| Q3 25 | $585.6M | — | ||
| Q2 25 | $433.7M | — | ||
| Q1 25 | $447.7M | — | ||
| Q4 24 | $445.6M | — | ||
| Q3 24 | $466.0M | — | ||
| Q2 24 | $488.2M | — | ||
| Q1 24 | $499.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.4M | $-24.8M |
| Free Cash FlowOCF − Capex | $10.2M | $-34.8M |
| FCF MarginFCF / Revenue | 7.6% | -33.5% |
| Capex IntensityCapex / Revenue | 2.4% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $26.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.4M | $-24.8M | ||
| Q3 25 | $1.9M | — | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $8.3M | — | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $17.9M | — | ||
| Q2 24 | $23.3M | — | ||
| Q1 24 | $10.6M | — |
| Q4 25 | $10.2M | $-34.8M | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $12.5M | — | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $35.6M | — | ||
| Q3 24 | $15.1M | — | ||
| Q2 24 | $19.2M | — | ||
| Q1 24 | $7.8M | — |
| Q4 25 | 7.6% | -33.5% | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 9.5% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 11.1% | — | ||
| Q2 24 | 11.7% | — | ||
| Q1 24 | 4.9% | — |
| Q4 25 | 2.4% | 9.6% | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | 2.5% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 416.65× | — | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 6.03× | — | ||
| Q2 24 | 6.15× | — | ||
| Q1 24 | 3.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEC
| Fabrication | $72.2M | 54% |
| Construction And Access | $19.2M | 14% |
| Tubes | $16.2M | 12% |
| Other Market | $11.9M | 9% |
| Agriculture | $7.7M | 6% |
| Military | $6.7M | 5% |
| Outdoor Sports | $1.7M | 1% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
